In Vivo · 2020 · 21 citations · 30 references
MedicineOncologyPharmacologyChemotherapyMolecular OncologyNeoplasiaCancer ProgressionCell Cycle SignalingMalignant NeoplasmsMicrorna BiogenesisMicrorna BiologyPancreatic CancerCancer Cell Proliferation InhibitionCell Cycle DynamicsCell Cycle InhibitionDna Synthesis InhibitionGemcitabine-based TherapyMicrorna In CancerMicrorna In Cell ProliferationMicrorna Regulation In Cancer
BACKGROUND/AIM: Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile. MATERIALS AND METHODS: Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo. RESULTS: Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models. CONCLUSION: Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.
30
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
Helmut Oettle, Stefan Post, P. Neuhaus et al. · JAMA · 2007 · 2.4K citations
Drug delivery with carbon nanotubes for in vivo cancer treatment
Zhuang Liu, Kai Chen, Corrine R. Davis et al. · PubMed · 2008 · 2.3K citations · Full text
Pharmacy, Oncology, Pharmacology +17